China Pediatric Pharmaceuticals (CPDU) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CPDU Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how China Pediatric Pharmaceuticals balances growth, leverage, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2014)
(Dec 31 2013) (Sep 30 2013) (Jun 30 2013) (Mar 31 2013)
Assets
Cash & cash equivalent1.04
Cash & Short-term Investments1.00
Accounts receivable1.31
Other Receivables, Net, Current0.09
Notes, Loans and Financing Receivable, Gross, Current NO4.89
Inventories0.03
Other Current Assets0.21
Total loans net1.23
Total Current Assets8.82
Equipment/Property/Plant Net0.70
Intangible Assets0.65
Other Assets, Noncurrent0.00
Total Assets10.16
Liabilities
Accounts Payable, Current AC0.01
Other Accounts Payable AndAccrued Liabilities0.46
Other Liabilities, Current0.00
Sales and Excise Tax Payable, Current0.07
Customer Deposits, Current0.01
Total Current Liabilities0.54
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Total Liabilities0.54
Stockholders' Equity
Common Stock Value0.04
Additional Paid In Capital Common Stock14.10
Retained Earnings / Accumulated Deficit-8.01
Other Equity3.48
Common Stockholder's Equity9.62
Total Stockholder's Equity9.62
Liabilities & Stockholder's Equity10.16
4 historic quarters locked

Sign in to unlock the full China Pediatric Pharmaceuticals balance sheet history.

About CPDU Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.